The new cancer therapeutics will be developed using both GenVec’s gene delivery platform and TheraBiologics’ neural stem cell (NSC) technology. Under the deal, GenVec will contribute technology, know-how,
The company’s AAT therapy is being examined in a clinical US Phase I/II trial that is evaluating 24 GvHD patients with inadequate response to steroid treatment following allogeneic
Takeda has licensed exclusive rights to use ImmunoGen’s antibody-drug conjugate (ADC) technology including its new DNA-acting IGN payload agents to develop and commercialize targeted anticancer therapeutics to up
Based in the recently reported nonclinical results, the company intends to start dosing in a Phase II trial of vepoloxamer in patients with chronic heart failure in the
Under the deal, scientists at CSHL and GSK will pursue drug development based on a new approach to regulate the enzymatic activity of the phosphatase PTP1B. The multiyear
Earlier in January, the company secured approval from the US Food and Drug Administration (FDA) for a new drug application (NDA) for the product. For the twelve months
As additional support to the clinical program for ALZ-801, the company had reported expanded post-hoc analyses of Phase III data with tramiprosate. Tramiprosate is the parent molecule of
As part of the deal, both the firms will support the development and potential commercialization of at least three cancer treatments over the next decade. The agreement also
In Japan, Repatha is being developed by Amgen Astellas BioPharma, a joint venture between Amgen and Astellas Pharma, a Japanese pharmaceutical firm. Repatha inhibits proprotein convertase subtilisin/kexin type
The ongoing Phase Ib randomized, double-blind, placebo-controlled, multiple-dose PRIME trial is evaluating the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of aducanumab. The interim analysis of PRIME reflects
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.